Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  Evotec AG    EVT   DE0005664809

EVOTEC AG

(EVT)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Evotec AG : There is still some upside potential

share with twitter share with LinkedIn share with facebook
share via e-mail
11/08/2018 | 03:31am EDT
long trade
Target price hit
Entry price : 19.67€ | Target : 24€ | Stop-loss : 16€ | Potential : 22.01%
Shares in Evotec do not show any sign of a slowdown in the ascending dynamic. Investors could bet on a continuation of the underlying trend.
Investors have an opportunity to buy the stock and target the € 24.
Chart EVOTEC AG
Duration : Period :
Evotec AG Technical Analysis Chart | MarketScreener
Full-screen chart
Summary
  • The company has poor fundamentals for a short-term investment strategy.

Strengths
  • Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
  • The group's high margin levels account for strong profits.
  • The group usually releases upbeat results with huge surprise rates.
  • Over the last twelve months, the sales forecast has been frequently revised upwards.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.

Weaknesses
  • The share is close to its long-term resistance in weekly data. Therefore, the potential should be limited. However, a further bullish movement when crossing this resistance will be a positive signal.
  • Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
  • The company's "enterprise value to sales" ratio is among the highest in the world.
  • The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 81.62 times its estimated earnings per share for the ongoing year.
  • For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
Evotec : There is still some upside potential

Ulrich Ebensperger
© Zonebourse.com 2018
share with twitter share with LinkedIn share with facebook
share via e-mail

Disclaimer: The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.

Financials (€)
Sales 2019 423 M
EBIT 2019 67,8 M
Net income 2019 52,1 M
Finance 2019 3,00 M
Yield 2019 -
P/E ratio 2019 61,93
P/E ratio 2020 54,77
EV / Sales 2019 7,71x
EV / Sales 2020 6,69x
Capitalization 3 265 M
Upcoming event on EVOTEC AG
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Average target price 25,1 €
Spread / Average Target 15%
EPS Revisions
Managers
NameTitle
Werner Lanthaler Chief Executive Officer
Wolfgang Plischke Chairman-Supervisory Board
Craig L. Johnstone Chief Operating Officer & Member-Management Board
Enno Spillner Chief Financial Officer
Cord E. Dohrmann Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
EVOTEC AG25.54%3 672
IQVIA HOLDINGS INC15.67%26 285
CELLTRION, INC.--.--%24 574
LONZA GROUP16.76%21 828
INCYTE CORPORATION15.84%15 847
EXACT SCIENCES CORPORATION43.69%11 596